Ziad S. Saad

Johnson & Johnson (United States) — United States

Neuroscience · Life Sciences

44h-index9.1kcitations113works10.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Functional Brain Connectivity Studies(45), Dementia and Cognitive Impairment Research(35), Alzheimer's disease research and treatments(32), Advanced MRI Techniques and Applications(24), Advanced Neuroimaging Techniques and Applications(22)

Publications113 total

External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Alzheimer s & Dementia·2025Open Access
Analysis of reasons for screen failure by participant race in the Phase 2 Auτonomy study in early Alzheimer's disease
Alzheimer s & Dementia·2025Open Access
Assessment of Association of Tau PET Spatial Patterns with Cognitive Domains in Participants with Early Alzheimer's Disease in the Phase 2 Auτonomy Trial
Alzheimer s & Dementia·2025Open Access
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Alzheimer s & Dementia·2025Open Access
Assessment of Association of Tau PET Spatial Patterns with Cognitive Domains in Participants with Early Alzheimer's Disease in the Phase 2 Auτonomy Trial
Alzheimer s & Dementia·2025Open Access
Prevalence and risk factors of cerebral microhemorrhages and superficial siderosis in cognitively unimpaired older adults: analysis from the CHARIOT‐PRO SubStudy
Alzheimer s & Dementia·2025Open Access
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau <scp>PET</scp> Clocks
Annals of Neurology·2025· 12 citedOpen Access
Differences in resting state and task-based EEG measures between patients with major depressive disorder and healthy controls
Clinical Neurophysiology·2025· 3 citedOpen Access
Alzheimer’s disease biological PET staging using plasma p217+tau
Communications Medicine·2025· 6 citedOpen Access
Plasma p217+tau accurately discriminates Intermediate or Advanced Alzheimer's Disease biological PET stages
Alzheimer s & Dementia·2024Open Access
Head‐to‐head evaluation of leading blood tests for amyloid pathology
Alzheimer s & Dementia·2024Open Access
Timing of changes in Alzheimer’s disease plasma biomarkers as assessed by amyloid and tau PET clocks
2024· 2 citedOpen Access
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
Alzheimer s & Dementia·2024· 116 citedOpen Access
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Alzheimer s & Dementia·2024· 38 citedOpen Access
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology
2024· 9 citedOpen Access
Alzheimer’s Disease biological PET staging using plasma p217+tau
2024Open Access
Alzheimer’s Disease biological PET staging using plasma p217+tau
2024Open Access
Processing, evaluating, and understanding FMRI data with afni_proc.py
Imaging Neuroscience·2024· 9 citedOpen Access
<i>APOE</i>ε4 potentiates the effects of Aβ pathology on the deposition of neurofibrillary tangles via tau phosphorylation
Alzheimer s & Dementia·2023Open Access
In‐vivo Braak Stage Distribution of Screened and Randomized Participants from Auτonomy, a Phase 2 Anti‐p‐tau Monoclonal Antibody Trial in Early Symptomatic Alzheimer’s Disease
Alzheimer s & Dementia·2023Open Access
page 1 of 6Next →

Frequent Co-authors

Robert W. Cox(17), Peter A. Bandettini(9), Hang Joon Jo(8), Stephen J. Gotts(7), Gang Chen(7), Alex Martin(7), Hartmuth C. Kolb(6), Daniel Glen(5), Richard C. Reynolds(5), Michael S. Beauchamp(4), Javier González-Castillo(4), Daniel A. Handwerker(4), Souheil Inati(3), Colin W. Hoy(3), K.M. Ropella(3), Edgar A. DeYoe(3), Henrik Zetterberg(3), Gallen Triana‐Baltzer(3), Wayne C. Drevets(3), Victor L. Villemagne(3)